By Estelle Haenel, Medical Director at Kayentis
Many chronic diseases such as invasive cancers, inflammatory disorders, cardiovascular, or central nervous system diseases can have a significant impact on patient mobility as well as hindering the ability of caregivers to accompany patients to clinic visits. Hybrid and decentralized clinical trials can provide these patients the opportunity to participate in a clinical trial or even receive a treatment to which they would otherwise not have access.
Decentralized Clinical Trials (DCTs) are recognized as being an integrated and necessary part of the new clinical trial paradigm and require specific considerations in addition to those for site-based clinical trials.
Specific therapeutic area requirements prevent some clinical trials taking place away from a clinical site. Additionally, the requirements of a particular patient population, protocol design specificities, or regulatory requirements also need to be considered.
To learn more about Kayentis, visit their Clinical Leader page.